Featured Trial
Our review committee has reviewed this trial and it meets our criteria for going above and beyond. Learn more about featured trials.
Clinical Trial Goal
To find out if the combination of isatuximab and lenalidomide is safe and works well to treat multiple myeloma that doctors consider high-risk after autologous BMT
You may be able to join this trial if you:
- Are 18 - 70 years old
- Have multiple myeloma that doctors consider high-risk
- Have had or plan to have an autologous BMT
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Isatuximab is a monoclonal antibody that targets CD38 on certain cells.
Lenalidomide is a drug that blocks growth of cancer cells.
You’ll get the following 2 - 6 months after autologous BMT:
Lenalidomide is a drug that blocks growth of cancer cells.
You’ll get the following 2 - 6 months after autologous BMT:
- Isatuximab – Given as an intravenous (IV) infusion
- Lenalidomide - A pill that you take by mouth
You may continue treatment for up to 3 years. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 6 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial.
Locations
M D Anderson Cancer CenterRECRUITING
Houston, Texas
Muzaffar Qazilbash, MD, 713-745-3458, mqazilba@mdanderson.org
Sponsors
collaborator: Sanofi, lead: M.D. Anderson Cancer Center
